{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:51:11Z","timestamp":1791323471806,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.pnpbp.2010.08.007","type":"journal-article","created":{"date-parts":[[2010,8,20]],"date-time":"2010-08-20T06:39:53Z","timestamp":1282286393000},"page":"1480-1483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["No alterations of brain GABA after 6months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia"],"prefix":"10.1016","volume":"34","author":[{"given":"Naoki","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiji","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kakeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Ikenouchi-Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakako","family":"Nakano-Umene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Katsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukunori","family":"Korogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2010.08.007_bb0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.brainresrev.2006.04.001","article-title":"Molecular and cellular mechanisms of altered GAD1\/GAD67 expression in schizophrenia and related disorders","volume":"52","author":"Akbarian","year":"2006","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0010","series-title":"A text Revision of Diagnostic and Statistical Manual of Mental Disorder","year":"2000"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0015","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0306-4522(96)00328-4","article-title":"Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects","volume":"75","author":"Benes","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00004424-199606000-00006","article-title":"Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydroxygen magnetic spectroscopy","volume":"31","author":"Choe","year":"1996","journal-title":"Investig Radiol"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0025","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.biopsych.2005.02.027","article-title":"Decreased prefrontal myoinositol in major depressive disorder","volume":"57","author":"Coupland","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmrb.1993.1055","article-title":"Absolute quantitation of water and metabolites in the human brain. I. Compartments and water","volume":"102","author":"Ernst","year":"1993","journal-title":"J Magn Reson Ser B"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0035","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders, Patient edition (SCID-P), version 2 New York State Psychiatric Institute, Biometrics Research, New York","author":"First","year":"1995"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0040","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-010-0124-8","article-title":"Alterations of GABA neurons and network oscillations in schizophrenia","author":"Gonzalez-Burgos","year":"2010","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.schres.2009.04.026","article-title":"Reduction of brain gamma-aminobutylic acid (GABA) concentrations in early-stage schizophrenia patients: 3T proton MRS study","volume":"112","author":"Goto","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0024-3205(87)90341-9","article-title":"[3H]Muscimol binding sites increased autopsied brains of chronic schizophrenics","volume":"40","author":"Hanada","year":"1987","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0060","doi-asserted-by":"crossref","first-page":"15718","DOI":"10.1073\/pnas.95.26.15718","article-title":"Pisu MG A decrease of reelin expression as a putative vulnerability factor in schizophrenia","volume":"95","author":"Impagnatiello","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0896-6273(00)00111-2","article-title":"Catching up on schizophrenia: natural history and neurobiology","volume":"28","author":"Lewis","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0080","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J","article-title":"Simultaneous in vivo spectral editing and water suppression","volume":"11","author":"Mescher","year":"1998","journal-title":"NMR Biomed"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pscychresns.2008.06.002","article-title":"Creatine abnormalities in schizophrenia and bipolar disorder","volume":"172","author":"Ongur","year":"2009","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0085","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mrm.1910300604","article-title":"Estimation of metabolite concentrations from localized in vivo proton NMR spectra","volume":"30","author":"Provenhcar","year":"1993","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0090","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1523\/JNEUROSCI.20-01-00485.2000","article-title":"Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory","volume":"20","author":"Rao","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0166-4328(88)90023-X","article-title":"Delayed response deficit in monkeys by locally disturbed prefrontal neuronal activity by bicuculline","volume":"31","author":"Sawaguchi","year":"1989","journal-title":"Behav Brain Res"},{"issue":"Suppl","key":"10.1016\/j.pnpbp.2010.08.007_bb0140","first-page":"22","article-title":"The Mini-Neuropsychiatric International Interview (M.I.N.I.): the development and validation of a structured diagnostic interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0304-3940(91)90653-B","article-title":"Evidence of glutamatergic deficiency in schizophrenia","volume":"121","author":"Sherman","year":"1991","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0304-3940(89)90819-7","article-title":"Reduced GABA uptake sites in the temporal lobe in schizophrenia","volume":"107","author":"Simpson","year":"1989","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2009.11.011","article-title":"GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study","volume":"117","author":"Tayoshi","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.biopsych.2004.10.019","article-title":"Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains","volume":"57","author":"Torrey","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archpsyc.1982.04290010065012","article-title":"CSF levels of gamma-aminobutyric acid in schizophrenia: low values in recently ill patients","volume":"39","author":"Van Kammen","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0925-4927(98)00006-7","article-title":"GABA and brain abnormalities in schizophrenia","volume":"82","author":"Van Kammen","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2010.08.007_bb0135","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1523\/JNEUROSCI.6158-09.2010","article-title":"GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression","volume":"30","author":"Yoon","year":"2010","journal-title":"J Neurosci"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610003106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610003106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:10:24Z","timestamp":1791321024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584610003106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0278584610003106"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2010.08.007","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No alterations of brain GABA after 6months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2010.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}